Cytokinetics, Inc. : Cytokinetics Announces Changes to Its Board of Directors

Cytokinetics, Inc. : Cytokinetics Announces Changes to Its Board of Directors

Steve Dow Will Not Stand for Re-Election at the Annual Meeting of
B. Lynne Parshall Has Been Appointed to the Company's Board

South San  Francisco,  CA,  February  8,  2013  -  Cytokinetics,  Incorporated 
(Nasdaq: CYTK) announced today that  Steve Dow has provided notification  that 
he will not stand for re-election to  the Company's Board of Directors at  its 
Annual Meeting  of  Shareholders  to occur  on  May  22, 2013.  Mr.  Dow  has 
indicated he will continue  his service to the  Cytokinetics' Board until  the 
expiration of his current term. Contemporaneously with Mr. Dow's notice,  the 
Board has  appointed Ms.  B.  Lynne Parshall,  Esq.  to the  company's  Board, 
effective February 7, 2013.

"We would like to  thank Steve for his  longstanding and dedicated service  to 
the company,"  stated  Robert  I.  Blum,  Cytokinetics'  President  and  Chief 
Executive Officer. "Steve has served on our Board since the company's founding
and we  are fortunate  to  have had  the benefit  of  his expertise  and  wise 
counsel. On behalf of Cytokinetics' management and our Board, we are  grateful 
for his strategic insights and professional oversight that have contributed to
the company's successes."

B. Lynne Parshall joins the Cytokinetics Board of Directors with over 21 years
of  legal,  financial,   manufacturing,  general   management  and   corporate 
development experience  in the  biopharmaceutical industry.  Ms. Parshall  is 
currently a member of the Board  of Directors and the Chief Operating  Officer 
of Isis Pharmaceuticals, Inc., a  public biopharmaceutical company focused  on 
antisense  drug   discovery   and   development.   Prior   to   joining   Isis 
Pharmaceuticals, Ms. Parshall was  a partner with the  firm of Cooley  Godward 
LLP, where  she  represented  health  care companies  in  a  general  practice 
specializing in corporate partnering and other technology-based  transactions. 
Ms. Parshall currently  serves on the  Board of Regulus  Therapeutics Inc.,  a 
public biopharmaceutical company co-founded by Isis. Ms. Parshall is a  member 
of the  American, California  and  San Diego  bar associations.  Ms.  Parshall 
received her  J.D.  from  Stanford  Law  School  and  her  B.A.  from  Harvard 

"We are pleased  to welcome  Lynne to  the Cytokinetics  Board. Her  extensive 
operational  and  business   development  experience,   particularly  in   the 
advancement and funding of potential  products directed to specialty care  and 
orphan drug designated indications, will be valuable to our company as we  may 
advance our own drug candidates in late-stage clinical trials." continued  Mr. 
Blum. "Lynne has successfully led the  strategic direction and growth of  Isis 
Pharmaceuticals over the last 20 years. We look forward to having the  benefit 
of her  biopharmaceutical operating  experience to  assist our  financial  and 
business development strategies and company planning." 

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide  (excluding Japan)  to develop  and commercialize  omecamtiv 
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization  participation  rights.  Cytokinetics  is  independently 
developing tirasemtiv, a skeletal muscle  activator, as a potential  treatment 
for  diseases  and  conditions  associated  with  aging,  muscle  wasting   or 
neuromuscular dysfunction. Tirasemtiv is currently  the subject of a Phase  II 
clinical trials program and has been granted orphan drug designation and  fast 
track status by  the U.S. Food  and Drug Administration  and orphan  medicinal 
product designation  by  the  European  Medicines  Agency  for  the  potential 
treatment  of  amyotrophic  lateral  sclerosis,  a  debilitating  disease   of 
neuromuscular  impairment  in   which  treatment   with  tirasemtiv   produced 
potentially clinically relevant  pharmacodynamic effects in  Phase II  trials. 
All of these  drug candidates  have arisen from  Cytokinetics' muscle  biology 
focused research activities  and are  directed towards  the cytoskeleton.  The 
cytoskeleton is a complex biological  infrastructure that plays a  fundamental 
role within every human cell. Additional information about Cytokinetics can be
obtained at

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to the properties and potential benefits of  Cytokinetics' 
drug candidates  and  the potential  advancement  of its  drug  candidates  in 
late-stage clinical trials. Such statements are based on management's  current 
expectations, but actual results  may differ materially  due to various  risks 
and uncertainties, including,  but not limited  to, potential difficulties  or 
delays in  the development,  testing, regulatory  approval and  production  of 
Cytokinetics' drug candidates and potential drug candidates that could slow or
prevent clinical development or product approval, including risks that current
and past  results  of  clinical  trials or  preclinical  studies  may  not  be 
indicative of  future  clinical trials  results  and that  Cytokinetics'  drug 
candidates and  potential drug  candidates may  have unexpected  adverse  side 
effects or inadequate therapeutic efficacy. For further information  regarding 
these and  other risks  related to  Cytokinetics' business,  investors  should 
consult Cytokinetics' filings with the Securities and Exchange Commission.

Joanna (Jodi) L. Goldstein
Manager, Marketing & Corporate Communications
(650) 624-3000


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.